Loading
Loading
Healthcare
Executive compensation benchmarks for 37 public companies in the pharmaceutical preparations industry.
$14.7M
37
$163.3M
206:1
Median
$14,663,742
Average
$17,960,246
25th Percentile
$9,473,819
75th Percentile
$17,279,869
Minimum
$794
Maximum
$163,293,744
Avg Pay Ratio
206:1
Companies
37
Click any company to see full compensation breakdown
The median pharmaceutical preparations CEO compensation is $14,663,742, based on 37 public companies. The average is $17,960,246. Note that CEO compensation includes salary, bonus, stock awards, option awards, and other compensation.
Matthew Gline of Roivant Sciences Ltd. is the highest paid pharmaceutical preparations CEO, with total compensation of $163,293,744 in FY2025.
The average CEO-to-median-employee pay ratio in the pharmaceutical preparations industry is 206:1. This means the average CEO earns 206 times what the median employee earns.
Data sourced from SEC filings (DEF 14A proxy statements). Last updated: April 16, 2026. Compensation figures are total annual compensation including salary, bonus, stock awards, and other compensation.
Compare CEO compensation across different industries or research specific companies.
| Company | CEO | Total Comp |
|---|---|---|
| Roivant Sciences Ltd. ROIV | Matthew Gline | $163.3M |
| JOHNSON & JOHNSON JNJ | J. Duato | $32.8M |
| ELI LILLY & Co LLY | David A. Ricks | $30.2M |
| AbbVie Inc. ABBV | Robert A. Michael | $27.3M |
| ABBOTT LABORATORIES ABT | Robert B. Ford, | $24.2M |
| ASTRAZENECA PLC AZN | Pascal Soriot | $23.8M |
| VERTEX PHARMACEUTICALS INC / MA VRTX | Reshma Kewalramani | $21.1M |
| BeOne Medicines Ltd. ONC | John V. Oyler | $20.8M |
| Merck & Co., Inc. MRK | Robert M. Davis | $20.8M |
| Nuvalent, Inc. NUVL | James R. Porter | $17.3M |
| Organon & Co. OGN | Kevin Ali | $17.1M |
| BridgeBio Pharma, Inc. BBIO | Neil Kumar | $15.6M |
| Jazz Pharmaceuticals plc JAZZ | Bruce C. Cozadd | $15.5M |
| TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA | Richard Francis | $15.5M |
| UNITED THERAPEUTICS Corp UTHR | Martine Rothblatt | $15.4M |
| Viatris Inc VTRS | Scott A. Smith | $15.3M |
| Alnylam Pharmaceuticals, Inc. ALNY | Yvonne L. Greenstreet | $14.9M |
| BIOMARIN PHARMACEUTICAL INC BMRN | Alexander Hardy | $14.9M |
| RHYTHM PHARMACEUTICALS, INC. RYTM | David P. Meeker | $14.7M |
| INSMED Inc INSM | William H. Lewis | $14.5M |
| CYTOKINETICS INC CYTK | Robert I. Blum | $14.4M |
| Avidity Biosciences, Inc. RNA | Sarah Boyce | $14.2M |
| MADRIGAL PHARMACEUTICALS, INC. MDGL | Bill Sibold | $12.2M |
| IONIS PHARMACEUTICALS INC IONS | Brett P. Monia | $10.7M |
| Axsome Therapeutics, Inc. AXSM | Herriot Tabuteau | $10.4M |
| CORCEPT THERAPEUTICS INC CORT | Joseph K. Belanoff | $9.9M |
| Merus N.V. MRUS | Sven (Bill) Ante Lundberg | $9.7M |
| Protagonist Therapeutics, Inc PTGX | Dinesh V. Patel | $9.5M |
| ARROWHEAD PHARMACEUTICALS, INC. ARWR | Christopher Anzalone | $9.0M |
| Grifols SA GRFS | Raimon Grifols Roura | $8.0M |
| PTC THERAPEUTICS, INC. PTCT | Matthew B. Klein | $7.4M |
| REGENERON PHARMACEUTICALS, INC. REGN | Leonard S. Schleifer | $6.8M |
| Cogent Biosciences, Inc. COGT | Andrew Robbins | $4.9M |
| Royalty Pharma plc RPRX | Christopher Hite | $1.3M |
| Summit Therapeutics Inc. SMMT | Mahkam Zanganeh | $1.2M |
| Abivax S.A. ABVX | Claret Financing | $108K |
| KAMADA LTD KMDA | Amir London | $794 |